Date: 2015-06-17
Type of information: R&D agreement
Compound: antibodies against an undisclosed number of targets provided by Pierre Fabre
Company: Pierre Fabre (France) ABCheck ( Czech Republic)
Therapeutic area: undisclosed
Type agreement: R&D
Action mechanism:
Disease: undisclosed
Details: * On April 2, 2014, AbCheck, a multi antibody discovery platforms company, has announced that it has entered into a research collaboration with Pierre Fabre, the third largest French pharmaceutical company. Under the agreement AbCheck will use its AbSieve discovery platform, which combines the Company’s proprietary phage and yeast display technologies, to deliver antibodies against an undisclosed number of targets provided by Pierre Fabre. The pharmaceutical company, which has full rights to any antibodies selected, will pay AbCheck discovery fees and milestone payments. Other financial and deal terms are not disclosed.
“Along with the recent acquisition of a new cancer therapeutic in immuno-oncology - the immune checkpoint modulator AUNP12 targeting the PD-1 pathway – this additional partnership with AbCheck further illustrates Pierre Fabre strategy to reinforce its portfolio in oncology,” added Frédéric Duchesne, President, Pierre Fabre Pharmaceuticals.
Financial terms:
Latest news: * On June 17, 2015, AbCheck and Pierre Fabre Pharmaceuticals announced that they have expanded their ongoing collaboration into a strategic research partnership in the field of human antibody discovery and optimization. Under the expanded agreement, AbCheck will use its proprietary human antibody discovery and optimization platform technologies, AbSieve and AbAccel, to deliver antibodies against two or more targets provided by Pierre Fabre per year over a period of three years. This period can be extended to up to five years. Pierre Fabre has secured full rights to all antibodies selected in exchange for discovery fees and milestone payments to AbCheck. Additional deal terms as well as financial details were not disclosed.
